A comparison of the newer COX-2 drugs and older nonnarcotic oral analgesics

被引：2
|
作者：
Sunshine, A
机构：
[1] NYU, Sch Med, Dept Clin Med, New York, NY 10012 USA
[2] Analges Dev Ltd, New York, NY USA
来源：
JOURNAL OF PAIN | 2000年 / 1卷 / 03期
关键词：
acetaminophen; COX-1; COX-2; NSAIDs; rofecoxib; salicylate;
D O I：
10.1054/jpai.2000.9817
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The newer COX-2 drugs are safer analgesics than the older NSAIDs. At the usual dose used in osteoarthritis, they have less analgesic effect than the older NSAIDs. The nonnarcotic analgesics such as acetaminophen, salicylate, NSAIDs, and the newer COX-2 drugs seem to have distinctly different mechanisms of action. In limited clinical trials, some of these drugs in combination give additive analgesia. Consideration should be given to using these drugs in combination, after suitable clinical trials, to enhance the efficacy of this category of analgesics.
引用
收藏
页码：10 / 13
页数：4
相关论文
共 50 条
  • [1] Diclofenac MACE risk versus older and newer COX-2 inhibitors
    Reactions Weekly, 2022, 1918 (1) : 10 - 10
  • [2] Are COX-2 selective inhibitors effective analgesics?
    McCormack, K
    Twycross, R
    PAIN REVIEWS, 2001, 8 (01): : 13 - 26
  • [3] More upheaval in COX-2 drugs
    不详
    CHEMICAL & ENGINEERING NEWS, 2004, 82 (50) : 13 - 13
  • [4] Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials
    Morten Schmidt
    Henrik Toft Sørensen
    Lars Pedersen
    Drug Safety, 2022, 45 : 983 - 994
  • [5] Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials
    Schmidt, Morten
    Sorensen, Henrik Toft
    Pedersen, Lars
    DRUG SAFETY, 2022, 45 (09) : 983 - 994
  • [6] The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors
    Wang, Z
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (14) : 1771 - 1777
  • [7] Expression of COX-2 enzyme in oral cancers
    Hietanen, E
    Nyman, T
    Syrjänen, S
    TOXICOLOGY, 2001, 164 (1-3) : 94 - 94
  • [8] Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors
    Kulkarni, SK
    Jain, NK
    Singh, A
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2000, 22 (05): : 291 - 298
  • [9] COX-2 expression in oral lichen planus
    Lysitsa, Stella
    Samson, Jacky
    Gerber-Wicht, Christine
    Lang, Ursula
    Lombardi, Tommaso
    DERMATOLOGY, 2008, 217 (02) : 150 - 155
  • [10] Induction of COX-2 in the oral cavity of smokers. Evidence for crosstalk between COX-2 and EGFR
    Moraitis, D
    Boyle, JO
    Cohen, E
    Carew, J
    Du, B
    Weksler, BB
    Subbaramaiah, K
    Dannenberg, AJ
    ORAL ONCOLOGY, 2005, 1 (01) : 115 - 116
12345